Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(1), С. 334 - 334
Опубликована: Янв. 2, 2025
The
first
part
of
this
review
highlighted
the
evolving
landscape
atherosclerosis,
noting
emerging
cardiometabolic
risk
factors,
growing
impact
exposomes,
and
social
determinants
health.
prominent
role
atherosclerosis
in
bidirectional
relationship
between
cardiovascular
disease
cancer
was
also
discussed.
In
second
part,
we
examine
complex
interplay
multimorbid
cardio-oncologic
patients,
harmful
environments
that
lend
a
“syndemic”
nature
to
these
chronic
diseases.
We
summarize
management
strategies
targeting
disordered
factors
mitigate
explore
molecular
mechanisms
enabling
more
tailored
therapies.
Importantly,
emphasize
early
interception
through
multifactorial
interventions
detect
subclinical
signs
(via
biomarkers
imaging)
treat
modifiable
prevent
clinical
events.
A
concerted
preventive
effort—referred
by
some
as
“preventome”—is
essential
reduce
burden
atherosclerosis-driven
diseases,
shifting
from
mere
proactive
promotion
“chronic
health”.
Язык: Английский
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights
Cardio-Oncology,
Год журнала:
2025,
Номер
11(1)
Опубликована: Фев. 11, 2025
Abstract
More
evidence-based
strategies
are
needed
for
preventing
and
managing
cancer
treatment-related
cardiovascular
toxicity
(CTR-CVT).
Owing
to
the
growing
body
of
evidence
supporting
their
cardioprotective
role
in
several
cardiac
injury
scenarios,
sodium-glucose
cotransporter
2
inhibitors
(SGLT2i)
may
be
beneficial
treating
CTR-CVT.
In
October
2024,
a
search
was
conducted
PubMed
database
review
full
studies
investigating
SGLT2i
against
We
identified
44
published/pre-print
3
ongoing
randomised
controlled
trial
across
eight
types
treatment
(anthracyclines,
platinum-containing
therapy,
immune
checkpoint
inhibitors,
HER2-targeted
therapies,
kinase
androgen
deprivation
multiple
myeloma
therapies
5-fluorouracil).
Most
used
animal
models
focussed
on
primary
prevention.
43
found
some
effect
CTR-CVT,
which
cases
included
ejection
fraction
decline
aberrations
electrophysiological
parameters.
Some
also
observed
effects
mortality.
A
central
triad
anti-inflammatory,
anti-oxidative
anti-apoptotic
mechanisms
likely
underlie
SGLT2i-mediated
cardioprotection
Overall,
this
research
suggests
that
promising
candidate
CTR-CVT
either
as
monotherapy
or
combination
with
other
drugs.
However,
literature
is
limited
no
prospective
trials
prevention
management
exist
most
existing
human
retrospective
data
based
diabetic
populations.
Future
work
must
focus
addressing
these
limitations
current
literature.
Язык: Английский
Cardioprotective Effects of Dapagliflozin and Trimetazidine on Doxorubicin-Induced Cardiotoxicity in Streptozotocin-Induced Type 1 Diabetic Rats via Endoplasmic Reticulum Stress
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(4), С. 1315 - 1315
Опубликована: Фев. 16, 2025
Background/Objectives:
Diabetic
cardiomyopathy
is
a
distinct
myocardial
dysfunction
characterized
by
structural
and
functional
changes
in
the
heart
that
occur
diabetic
patients
independently
of
coronary
artery
disease
or
hypertension.
It
closely
associated
with
oxidative
stress,
inflammation,
mitochondrial
dysfunction,
endoplasmic
reticulum
(ER)
contributes
to
progressive
cardiac
damage.
This
study
aimed
evaluate
cardioprotective
effects
dapagliflozin
(DAPA)
trimetazidine
(TMZ)
rat
model
doxorubicin-induced
streptozotocin-induced
diabetes,
focusing
on
their
potential
mechanisms
related
ER
stress.
Methods:
A
total
48
Sprague
Dawley
rats
aged
6-8
weeks
were
randomly
distributed
equally
into
six
cages.
The
diabetes
was
induced
intraperitoneal
administration
streptozotocin
(STZ)
blood
glucose
levels
above
250
mg/dL
considered
diabetic.
For
those
cardiotoxicity
injection
5
mg/kg/week
doxorubicin
(DOXO)
for
4
weeks.
After
cumulative
dose
20
mg/kg
doxorubicin,
week
break
given,
followed
TMZ
(10
mg/kg)
and/or
DAPA
treatment
groups.
Results:
STZ
caused
significant
degeneration
cardiomyocytes.
With
addition
DOXO
(STZ
+
DOXO),
cardiomyocyte
became
more
severe.
When
groups
histopathologically
evaluated
based
parameters
degenerative
cardiomyocytes,
vascular
congestion,
edema,
it
shown
both
DAPA,
whether
applied
alone
combination,
reduced
damage
tissue.
Both
damage,
combination
provided
lowest
level
through
stress
pathway
reducing
GRP
78
CHOP
positivity.
Conclusions:
reduce
have
protective
against
diabetic-induced
cardiotoxicity.
Combination
therapy
found
be
effective
than
alleviating
appears
carry
cell
individuals
diabetes.
Язык: Английский
Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure
European Journal of Pharmacology,
Год журнала:
2024,
Номер
982, С. 176934 - 176934
Опубликована: Авг. 23, 2024
Язык: Английский
SNX3 Promotes Doxorubicin-Induced Cardiomyopathy by Regulating GPX4-Mediated Ferroptosis
International Journal of Medical Sciences,
Год журнала:
2024,
Номер
21(9), С. 1629 - 1639
Опубликована: Янв. 1, 2024
The
complete
molecular
mechanism
underlying
doxorubicin-induced
cardiomyopathy
remains
incompletely
elucidated.
In
this
investigation,
we
engineered
mice
with
cardiomyocyte-specific
Язык: Английский
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(20), С. 11299 - 11299
Опубликована: Окт. 21, 2024
Cancer
patients,
especially
long
cancer
survivors,
are
exposed
to
several
cardio-metabolic
diseases,
including
diabetes,
heart
failure,
and
atherosclerosis,
which
increase
their
risk
of
cardiovascular
mortality.
Therapy
with
glucagon-like
peptide
1
(GLP1)
receptor
agonists
demonstrated
beneficial
effects,
atherosclerosis
failure
prevention.
Cardiovascular
outcome
trials
(CVOTs)
suggest
that
GLP-1
RA
could
exert
cardiorenal
benefits
systemic
anti-inflammatory
effects
in
patients
type-2
diabetes
through
the
activation
cAMP
PI3K/AkT
pathways
inhibition
NLRP-3
MyD88.
In
this
narrative
review,
we
highlight
biochemical
properties
a
deep
analysis
clinical
preclinical
evidence
primary
prevention
cardiomyopathies.
The
overall
picture
review
encourages
study
as
potential
strategy
against
atherosclerosis.
Язык: Английский
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 30, 2024
Cardiovascular
diseases
(CVD)
pose
a
significant
threat
to
human
health
due
their
high
mortality
and
morbidity
rates.
Despite
advances
in
treatments,
the
prevalence
impact
of
cardiovascular
disease
continue
increase.
Sodium-glucose
transporter
2
inhibitors
(SGLT2i),
initially
approved
for
treatment
type
diabetes,
have
important
research
value
promising
applications
reducing
CVD
risk,
especially
heart
failure
(HF)
atherosclerosis
patients
with
(ASCVD).
This
study
aims
comprehensively
review
latest
progress,
trends,
cutting-edge
hot
spots,
future
development
directions
SGLT2i
field
through
bibliometric
analysis.
Язык: Английский
Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
Hearts,
Год журнала:
2024,
Номер
5(4), С. 529 - 546
Опубликована: Ноя. 1, 2024
Sodium
glucose
cotransporter-2
inhibitors
(SGLT2i),
originally
developed
for
type
II
diabetes
mellitus,
have
recently
been
approved
the
treatment
of
heart
failure
in
both
diabetic
and
non-diabetic
patients
due
to
their
significant
cardiovascular
benefits.
Beyond
established
role
management,
current
research
is
exploring
potential
applications
SGLT2
field
cardio-oncology.
This
interest
driven
by
dual
possible
benefits:
cardioprotection
against
adverse
effects
antitumor
therapies
inherent
properties.
Patients
affected
cancer
often
face
challenge
managing
toxicity
induced
antineoplastic
treatments.
shown
promise
mitigating
toxicities,
thereby
enhancing
health
these
patients.
Additionally,
emerging
evidence
suggests
that
may
possess
direct
effects,
further
contributing
therapeutic
oncology.
review
aims
provide
a
comprehensive
overview
molecular
mechanisms
through
which
exert
cardioprotective
effects.
Furthermore,
we
will
examine
body
supporting
use
cardio-oncology
setting.
Язык: Английский